Skip to NavigationSkip to content


New ICER report reveals most cost-effective rheumatoid arthritis therapies

The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of three JAK inhibitors for treating rheumatoid arthritis (RA): AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib), and Eli Lilly’s Olumiant (baricitinib).

Head-to-head data revealed that Rinvoq demonstrated “statistically-significant but modestly higher rates of disease remission and improvement in other important outcomes” compared to AbbVie’s best-selling drug Humira; the report asserted that it could be assumed with “moderate certain

Pfizer's Humira biosimilar secures FDA approval, due to launch in 2023

Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb),  its biosimilar version of AbbVie’s Humira, the world’s best-selling drug,  

Pfizer’s therapy is now authorised for use in all approved indications of its reference product, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.

International revenue for world's best-selling drug Humira falls 33.5% in the face of biosimilar competition

With the release of its Q3 financial results, AbbVie confirmed that international revenues for its blockbuster therapy Humira (adalimumab) – the best-selling drug in the world – had taken a considerable hit in the face of biosimilar competition, falling 33.5% on a reported basis.

Total global revenues for the drug stood at $4.936 billion, a much stronger showing compared to the $1.049 billion generated internationally, and only fell by 3.7% overall.

Despite some advantages, Novartis' Cosentyx fails to outclass Humira in active psoriatic arthritis

Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – currently the world’s best-selling drug – in the treatment of active psoriatic arthritis (PsA).

While details on the findings of the study were scant, Novartis confirmed that its drug exhibited “numerically higher results” compared to AbbVie’s therapy with “statistically significant advantages” recorded in a pre-specified sensitivity analysis.

Takeda's Entyvio outperforms AbbVie's Humira in moderate-to-severe ulcerative colitis

Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha (TNFα) biologic Humira (adalimumab) in the treatment of moderately to severely active ulcerative colitis (UC).

Data showed that 34.2% of anti-TNFα-naïve patients treated with Entyvio saw clinical remission after 52 weeks of treatment compared to 24.3% with Humira, meeting the trial’s primary endpoint, while these rates stood at 20.3% in anti-TNFα-experienced patients compared to 16%.

Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US

It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s best-selling medicine – has received marketing authorisation from the FDA.

The approval for the drug, known as Hadlima and developed by Samsung Bioepis, covers the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis, just like its reference product.

FDA approves Pfizer's Herceptin biosimilar Trazimera

Patients in the US will now be able to access another biosimilar version of Herceptin (trastuzumab) with the FDA approval of Pfizer’s Trazimera in the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Data supplied with the application supported the similarity of Trazimera to its reference product, including clinical equivalence and no clinically meaningful differences between them.

Eli Lilly's Taltz shows superiority over AbbVie's Humira

A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naïve when compared to AbbVie's Humira.

 The Phase IIIb/IV SPIRIT-H2H study, 566 patients with active PsA demonstrates Taltz’s superiority over the world’s bestselling drug.

NHS to save £300 million by switching to Humira biosimilars

NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of AbbVie’s best-selling anti-inflammatory drug Humira (adalimumab), bringing the current annual total spent on the drug down by 75%.

The saving is the biggest saving in NHS history from a single drug negotiation and comes in at twice as much as previous estimates. The organisation said that the savings would be enough to pay for 11,700 more community nurses or 19,800 more breast cancer treatments.

Samsung and Bioepis launch third Humira biosimilar in Europe

Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) in Europe.

Like its reference product, it is authorised for use in a range of indications including rheumatoid and psoriatic arthritis, axial spondyloarthritis, psoriasis, Crohn’s disease, ulcerative colitis and uveitis, as well as Crohn’s disease, paediatric plaque psoriasis and idiopathic arthritis in children.<

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches